Status:

COMPLETED

2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer

Lead Sponsor:

Ohio State University Comprehensive Cancer Center

Conditions:

Recurrent Colon Cancer

Recurrent Rectal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This pilot phase II studies how well computed tomography (CT) and positron emission tomography (PET) imaging works in detecting disease in patients undergoing surgery for metastatic colorectal cancer....

Detailed Description

PRIMARY OBJECTIVES: I. To determine the feasibility of rigidly (linearly) registering PET to CT images and applying this fused dataset to guide surgery with an image-guided navigation system and a ha...

Eligibility Criteria

Inclusion

  • Patients with histologically-confirmed colorectal carcinoma and preoperative PET scan with evidence of hypermetabolic lesions suspicious for cancer will be eligible for this study. In cases of primary cancer, there must be a tissue-confirmed diagnosis. In recurrent cases, patients must have clinical evidence by CT or MRI of disease suitable for resection.
  • Patients must be candidates for clinically indicated surgery.
  • Patients with recurrent disease may have had prior surgery and/or chemotherapy with no limit to the number of prior therapeutic procedures or chemotherapeutic regimens.
  • Patients must have a performance status of 0, 1 or 2 by ECOG(Eastern Cooperative Oncology Group)standards.
  • Patients must give written informed consent including consent to have IV line placed for FDG administration.
  • Patients must be at least 18 years of age. Children under the age of 18 are excluded from the study due to the rarity of colorectal cancer in children.
  • Because radiolabeled agents are known to be teratogenic, women of child-bearing potential and men must agree to use an acceptable form of contraception prior to study entry and for the duration of the study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Organ function requirements: Patients must have organ and marrow function adequate to undergo laparotomy. Specifically:
  • Serum creatinine \< 2.0 mg/dl
  • Serum bilirubin \< 2.0 mg/dl
  • AST(aspartate aminotransferase,serum glutamate oxaloacetate transaminase, serum glutamate oxaloacetate transaminase,serum glutamate pyruvate transaminase)\[SGOT\]/ALT\[SGPT\]\<4 times institutional upper limit of normal
  • Total WBC(white blood cell)\>4,000/mm3 or ANC(absolute neutrophil count)\> 1,500/mm3
  • Platelets \> 100,000/mm3
  • Hgb \>10g/dl
  • Patient must have no clinically significant cardiac disease (New York Heart Association Class III/IV); no serious infection requiring treatment with antibiotics; no other serious ill-ness or illness requiring the use of steroids; no clinically significant pulmonary disease or other illness that would contraindicate or increase the risk of complications at surgery.
  • Fasting blood sugar less than 120 mg/dl

Exclusion

  • Patients with active CNS (central nervous system)tumor involvement are ineligible.
  • Any patient who has retained childbearing potential will not be pregnant or lactating and must use adequate contraception to assure avoidance of conception.
  • Body size prohibits use of the diagnostic equipment (portable CT scanner).
  • Tumor burden is so great (as determined by preoperative PET scanning or intraoperative findings) that further surgery is not advised.
  • If lesions are detected with preoperative CT but not with PET scanning (in other words, all patients will have a positive PET scan as part of the inclusion criteria).

Key Trial Info

Start Date :

March 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2009

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT01821105

Start Date

March 1 2004

End Date

November 1 2009

Last Update

March 2 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ohio State University Medical Center

Columbus, Ohio, United States, 43210